摘要
目的研究重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对强直性脊柱炎(AS)的临床治疗效果。方法以2009年4月～2010年4月本院收治的60例AS患者为研究对象,随机分为观察组和对照组各30例,观察组采用注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗,对照组采用柳氮磺吡啶治疗,比较两组的治疗效果。结果观察组30例患者在治疗6周时的总有效率为93.3%,对照组30例患者治疗6周时的总有效率为53.3%,观察组总有效率明显优于对照组,差异有统计学意义(P<0.05)。结论注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白用于治疗AS可使患者的临床症状得到明显缓解,且见效时间较短,相对柳氮磺吡啶具有显著的治疗优势。
Objective To study the clinical treatment effect of type Ⅱ recombinant human tumor necrosis factor receptor-antibody fusion protein injection in the treatment of ankylosing spondylitis （AS）. Methods Sixty patients with AS admitted to our hospital from April 2009 to April 2010 were randomly divided into observation group and control group,with 30 patients in each group,the observation group were received the type Ⅱ recombinant human tumor necrosis factor receptor-antibody fusion protein injection treatment and the control group were given sulfasalazine treatment, the clinical efficacy was compared between two goups.Results In the observation group,the total treatment effective rate at the 6th week was 93.3%,while that in the control group was 53.3%,the observation was better than that of the control group,with statstically significant difference （P＆lt;0.05）.Conclusion In the treatment of AS,type Ⅱ recombinant human tumor necrosis factor receptor-antibody fusion protein can alleviate the patients ’ clinical symptoms significantly and quickly,which has significant treatment advantages over sulfasalazine.
出处
《中国当代医药》
2013年第21期87-88,共2页
China Modern Medicine
基金
广东省潮州市医学科研项目(2013-4)
关键词
强直性脊柱炎
抗肿瘤坏死因子
注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白
Ankylosing spondylitis
Anti-tumor necrosis factor
Type Ⅱ recombinant human tumor necrosis factor receptor-antibody fusion protein injection
